MedTrace Logo

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

NCT00209950 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2007-03-30

No results posted yet for this study

Summary

To evaluate the safety and tolerability of gaboxadol in primary insomnia

Conditions

  • Primary Insomnia

Interventions

DRUG

Gaboxadol

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

  • Please contact: Annelies van der Hammen Legters · H. Lundbeck A/S

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2005-09-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00209950 on ClinicalTrials.gov